Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code AGR

16. Specific lobbying issues

Coronavirus (COVID-19) Pandemic
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Increased Borrowing Authority for the Commodity Credit Corporation (CCC)
---Priority Zoonotic Animal Drugs

Foreign Agricultural Biotechnology Laws and Regulations
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
---Korea Biotechnology Regulations

Funding for Biomass Crop Assistance Program
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021

Funding for the USDA
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---Farm Bill Programs Energy Title IX
---Increased Borrowing Authority for the Commodity Credit Corporation (CCC)

Genetically Engineered (GE) Animals
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
------Amendment on GE Salmon Labeling
---FDA Regulatory Approach to Animal Biotechnology
---Priority Zoonotic Animal Drugs
---USDA Authority to Review Animal Biotechnology

Genetically Engineered (GE) Plants
---EPA Regulatory Approach to Gene Editing

The United States-Mexico-Canada Agreement
---Ag-Biotech Provisions

US-China Trade Negotiations
---Ag Biotech Provisions

US-Japan Trade Agreement
---Ag-Biotech Provisions

US-UK Trade Agreement
---Ag-Biotech Provisions

USDA/APHIS Agricultural Biotechnology Regulations
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---Regulatory Treatment of Gene Edited Products

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), U.S. Trade Representative (USTR), Natl Economic Council (NEC), White House Office, Office of the Vice President of the United States, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ANI

16. Specific lobbying issues

Genetically Engineered (GE) Animals
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
------Amendment on GE Salmon Labeling
---FDA Regulatory Approach to Animal Biotechnology
---Priority Zoonotic Animal Drugs
---USDA Authority to Review Animal Biotechnology

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Natl Economic Council (NEC), White House Office, Office of the Vice President of the United States, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

Coronavirus (COVID-19) Pandemic
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---H.R.6201: Families First Coronavirus Response Act of 2020

Funding for Antimicrobial Resistance Programs
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.4100/S.1712: DISARM Act of 2019
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021

Funding for Biofuels
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6379: Take Responsibility for Workers and Families Act of 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---Department of the Interior, Environment, and Related Agencies Appropriations Act for FY 2021
---Energy and Water Development and Related Agencies Appropriations Act for FY 2021
---Incentives for Sustainable Aviation Fuels
---Increased Borrowing Authority for the Commodity Credit Corporation (CCC)
---Transportation, and Housing and Urban Development, and Related Agencies Act for FY 2021

Funding for Biomass Crop Assistance Program
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021

Funding for Biorefineries
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---Energy and Water Development and Related Agencies Appropriations Act for FY 2021
---Increased Borrowing Authority for the Commodity Credit Corporation (CCC)

Funding for Coronavirus (COVID-19) Small Business Loans
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020

Funding for FDA
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021

Funding for Health Resources and Services Administration (HRSA) - Vaccine Injury Compensation Program (VICP)
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021

Funding for National Institutes of Health
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021

Funding for Renewable Chemicals/Bio-based Products
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---Energy and Water Development and Related Agencies Appropriations Act for FY 2021
---Increased Borrowing Authority for the Commodity Credit Corporation (CCC)

Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021

Funding for the HHS Office of Infectious Disease and HIV/AIDS Policy
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021

Funding for the USDA
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---Farm Bill Programs Energy Title IX
---Increased Borrowing Authority for the Commodity Credit Corporation (CCC)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Treasury - Dept of, Small Business Administration (SBA), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Natl Institutes of Health (NIH), Agriculture - Dept of (USDA), Office of the Vice President of the United States, White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CHM

16. Specific lobbying issues

Funding for Renewable Chemicals/Bio-based Products
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---Energy and Water Development and Related Agencies Appropriations Act for FY 2021
---Increased Borrowing Authority for the Commodity Credit Corporation (CCC)

Renewable Chemicals/Bio-based Products (Non-Funding)
---H.R.2051/S.999: Sustainable Chemistry Research and Development Act of 2019
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---Bioeconomy Research and Development Act of 2020 (Discussion Draft House)
---Climate Leadership and Environmental Action for our Nations (CLEAN) Future Act (Discussion Draft House)
---Investment Tax Credit
---Production Tax Credit

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Bayh-Dole Act/Tech Transfer
---Bayh-Dole 40th Anniversary
---March-In Rights

Compulsory Licensing
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019

Drug Patenting
---H.R.19/S.3129: Lower Costs, More Cures Act of 2019
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.1188/S.366: Forcing Limits on Abusive and Tumultuous prices (FLAT) prices Act of 2019
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---H.R.1503: Orange Book Transparency Act of 2019
---H.R.1520: Purple Book Continuity Act of 2019
---H.R.3199: Terminating the Extension of Rights Misappropriated (TERM) Act of 2019
---H.R.3991: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019
---S.64: Preserve Access to Affordable Generics and Biosimilars Act of 2019
---S.659: Biologic Patent Transparency Act of 2019
---S.1416/H.R.4398/H.R.3991/H.R.5133: Affordable Prescriptions for Patients Act of 2019
---S.1617: Second Look at Drug Patents Act of 2019
---S.1895: Lower Health Care Costs for Patients Act of 2019

Intellectual Property International Enforcement
---China
---India

Inter Partes Review
---H.R.1503: Orange Book Transparency Act of 2019
---H.R.3666/S.2082: Support Technology and Research for Our Nation's Growth and Economic Resilience (STRONGER) Patents Act of 2019
---S.1617: Second Look at Drug Patents Act of 2019
---S.440 PACED Act of 2019
---Implementation of the America Invents Act of 2011

Patent Reform
---H.R.3199: Terminating the Extension of Rights Misappropriated (TERM) Act of 2019
---Patent Litigation Reforms

Patenting of Biological Inventions
---Section 101 Modernization

The United States-Mexico-Canada Agreement
---IP Provisions

US-China Trade Negotiations
---IP Provisions

US-Japan Trade Agreement
---IP Provisions

US-Kenya Trade Agreement
---IP Provisions

US-UK Trade Agreement
---IP Provisions

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Patent & Trademark Office (PTO), Office of the Vice President of the United States

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CSP

16. Specific lobbying issues

Drug Importation
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---General

Genetically Engineered (GE) Animals
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
------Amendment on GE Salmon Labeling
---FDA Regulatory Approach to Animal Biotechnology
---Priority Zoonotic Animal Drugs
---USDA Authority to Review Animal Biotechnology

Opioid Crisis
---General
---Implementation of the SUPPORT for Patients and Communities Act of 2018

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Natl Economic Council (NEC), White House Office, Office of the Vice President of the United States, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ENG

16. Specific lobbying issues

Biofuels (Non-Funding)
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.3006: Support RFS Integrity Act of 2019
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---H.R.4385: Small Refinery Exemption Fairness Act of 2019
---H.R.6379: Take Responsibility for Workers and Families Act of 2020
---S.1840: A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes.
---Climate Leadership and Environmental Action for our Nations (CLEAN) Future Act (Discussion Draft House)
---Incentives for Sustainable Aviation Fuels
---RFI from House Select Committee on the Climate Crisis
---Small Refinery Waivers
---Sustainable Aviation Fuels Tax Credit

Funding for Biofuels
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6379: Take Responsibility for Workers and Families Act of 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---Department of the Interior, Environment, and Related Agencies Appropriations Act for FY 2021
---Energy and Water Development and Related Agencies Appropriations Act for FY 2021
---Incentives for Sustainable Aviation Fuels
---Increased Borrowing Authority for the Commodity Credit Corporation (CCC)
---Transportation, and Housing and Urban Development, and Related Agencies Act for FY 2021

Funding for Biomass Crop Assistance Program
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021

Funding for Biorefineries
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---Energy and Water Development and Related Agencies Appropriations Act for FY 2021
---Increased Borrowing Authority for the Commodity Credit Corporation (CCC)

Renewable Fuel Standard (RFS)
---H.R.3006: Support RFS Integrity Act of 2019
---H.R.4385: Small Refinery Exemption Fairness Act of 2019
---S.1840: A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes.
---Climate Leadership and Environmental Action for our Nations (CLEAN) Future Act (Discussion Draft House)
---Cellulosic Registration Applications for Corn Kernel Fiber
---RFI from House Select Committee on the Climate Crisis
---RFS Reform
---Small Refinery Waivers

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code FOO

16. Specific lobbying issues

Genetically Engineered (GE) Animals
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
------Amendment on GE Salmon Labeling
---FDA Regulatory Approach to Animal Biotechnology
---Priority Zoonotic Animal Drugs
---USDA Authority to Review Animal Biotechnology

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), White House Office, Natl Economic Council (NEC), Office of the Vice President of the United States, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code FUE

16. Specific lobbying issues

Biofuels (Non-Funding)
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.3006: Support RFS Integrity Act of 2019
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---H.R.4385: Small Refinery Exemption Fairness Act of 2019
---H.R.6379: Take Responsibility for Workers and Families Act of 2020
---S.1840: A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes.
---Climate Leadership and Environmental Action for our Nations (CLEAN) Future Act (Discussion Draft House)
---Incentives for Sustainable Aviation Fuels
---RFI from House Select Committee on the Climate Crisis
---Small Refinery Waivers
---Sustainable Aviation Fuels Tax Credit

Funding for Biofuels
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6379: Take Responsibility for Workers and Families Act of 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---Department of the Interior, Environment, and Related Agencies Appropriations Act for FY 2021
---Energy and Water Development and Related Agencies Appropriations Act for FY 2021
---Incentives for Sustainable Aviation Fuels
---Increased Borrowing Authority for the Commodity Credit Corporation (CCC)
---Transportation, and Housing and Urban Development, and Related Agencies Act for FY 2021

Funding for Biomass Crop Assistance Program
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021

Funding for Biorefineries
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---Energy and Water Development and Related Agencies Appropriations Act for FY 2021
---Increased Borrowing Authority for the Commodity Credit Corporation (CCC)

Renewable Fuel Standard (RFS)
---H.R.3006: Support RFS Integrity Act of 2019
---H.R.4385: Small Refinery Exemption Fairness Act of 2019
---S.1840: A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes.
---Climate Leadership and Environmental Action for our Nations (CLEAN) Future Act (Discussion Draft House)
---Cellulosic Registration Applications for Corn Kernel Fiber
---RFI from House Select Committee on the Climate Crisis
---RFS Reform
---Small Refinery Waivers

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

21st Century Cures Act 2.0
---RFI from House Energy and Commerce Committee

340B Drug Discount Program
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021

Biodefense Research, Development and Procurement Issues (Non-funding)
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---H.R.6201: Families First Coronavirus Response Act of 2020
---Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act of 2019
---National Biodefense Strategy

Biosimilars
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---H.R.1520: Purple Book Continuity Act of 2019
---S.64: Preserve Access to Affordable Generics and Biosimilars Act of 2019
---S.659: Biologic Patent Transparency Act of 2019
---Implementation and Reauthorization of the Biosimilar User Fee Act of 2017

Coronavirus (COVID-19) Pandemic
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.4100/S.1712: DISARM Act of 2019
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---H.R.6201: Families First Coronavirus Response Act of 2020
---Drug Supply Chain Management
---Home Administration of Part B Drugs
---Medicare Reimbursement Policies
---Patient Cost-Sharing and Smoothing
---R&D Funding for Medical Countermeasures
---Reasonable Pricing Provisions

Diagnostics and Personalized Medicine Regulation and Oversight
---H.R.6102/S3404: VALID Act of 2020

Drug Evaluation and Review
---S.1617: Second Look at Drug Patents Act of 2019
---Patient-Focused Drug Development
---Regulatory Reform & Modernization
---Use of Real-World Evidence

Drug Importation
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---General

Drug Manufacturing, Quality & Distribution
---Drug Shortages
---Supply Chain Integrity and Traceability

Drug Patenting
---H.R.19/S.3129: Lower Costs, More Cures Act of 2019
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.1188/S.366: Forcing Limits on Abusive and Tumultuous prices (FLAT) prices Act of 2019
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---H.R.1503: Orange Book Transparency Act of 2019
---H.R.1520: Purple Book Continuity Act of 2019
---H.R.3199: Terminating the Extension of Rights Misappropriated (TERM) Act of 2019
---H.R.3991: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019
---S.1416/H.R.4398/H.R.3991/H.R.5133: Affordable Prescriptions for Patients Act of 2019
---S.1617: Second Look at Drug Patents Act of 2019
---S.1895: Lower Health Care Costs for Patients Act of 2019
---S.64: Preserve Access to Affordable Generics and Biosimilars Act of 2019
---S.659: Biologic Patent Transparency Act of 2019

Drug Pricing
---H.R.3: Lower Drug Costs Now Act of 2019
---H.R.19/S.3129: Lower Costs, More Cures Act of 2019
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.1188/S.366: Forcing Limits on Abusive and Tumultuous Prices (FLAT) Prices Act of 2019
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---H.R.1503: Orange Book Transparency Act of 2019
---H.R.1520: Purple Book Continuity Act of 2019
---H.R.2376/S.1227: Prescription Pricing for the People Act of 2019
---H.R.2387: STOP GAMES Act of 2019
---H.R.3199 Terminating the Extension of Rights Misappropriated (TERM) Act of 2019
---H.R.3991 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---S.64: Preserve Access to Affordable Generics and Biosimilars Act of 2019
---S.1416/H.R.4398/H.R.3991/H.R.5133: Affordable Prescriptions for Patients Act of 2019
---S.1617: Second Look at Drug Patents Act of 2019
---S.1895: Lower Health Care Costs for Patients Act of 2019
---S.2543: Prescription Drug Pricing Reduction Act of 2019
---CMMI Authority
---General
---HHS Blueprint to lower drug prices and reduce out of pocket costs
---International Pricing Index Proposal
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021
---Reasonable Pricing Provisions

Funding for Antimicrobial Resistance Programs
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.4100/S.1712: DISARM Act of 2019
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021

Funding for FDA
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021

Funding for Health Resources and Services Administration (HRSA)
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021

Funding for National Institutes of Health
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021

Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021

Medicaid
---H.R.5741: Strengthening Innovation in Medicare and Medicaid Act of 2020
---S.2543: Prescription Drug Pricing Reduction Act of 2019
---Alternative payment arrangements for gene therapies
---Pricing and Rebates

Opioid Crisis
---General
---Implementation of the SUPPORT for Patients and Communities Act of 2018

Orphan Drug Issues
---H.R.4712: Fairness in Orphan Drug Exclusivity Act of 2019
---Tax Credit

Rare Pediatric Disease Priority Review
---H.R.4439: Creating Hope Reathorization Act of 2019

Reimbursement and Coverage of Innovative Products
---H.R.3: Lower Drug Costs Now Act of 2019
---H.R.19/S.3129: Lower Costs, More Cures Act of 2019
---S.2326: New Opportunities for Value that Extend Lives (NOVEL) Act of 2019
---S.2543: Prescription Drug Pricing Reduction Act of 2019
---Administration Rebate Rule
---CMMI Authority
---HHS Blueprint to lower drug prices and reduce out of pocket costs
---Home Administration of Part B Drugs
---International Pricing Index Proposal
---Medicare Part B Physician-Administered Products
---Medicare Part D Prescription Drug Program
---Patient Cost-Sharing and Smoothing
---Step Therapy
---Support of Patient Premiums and Cost-Sharing Obligations
---Surprise Billing
---Value-based Contracting and Communications

The United States-Mexico-Canada Agreement
---IP Provisions

US-China Trade Negotiations
---IP Provisions

US-Japan Trade Agreement
---IP Provisions

US-Kenya Trade Agreement
---IP Provisions

US-UK Trade Agreement
---IP Provisions

Vaccine Injury Compensation Program Tax
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 202
---H.R.1973/S.1654: Vaccine Access Improvement Act of 2019
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---H.R.6201: Families First Coronavirus Response Act of 2020

Vaccines and Infectious Diseases
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.5076/S.1872: Protecting Seniors through Immunizations Act of 2019
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---H.R.6201: Families First Coronavirus Response Act of 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021
---Vaccine and Anti-Microbial Resistance Product Development and Incentives

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), White House Office, U.S. Trade Representative (USTR), Health & Human Services - Dept of (HHS), Council of Economic Advisers (CEA), Food & Drug Administration (FDA), Natl Economic Council (NEC), Office of the Vice President of the United States, Natl Institutes of Health (NIH)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HOM

16. Specific lobbying issues

Biodefense Research, Development and Procurement Issues (Non-funding)
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---H.R.6201: Families First Coronavirus Response Act of 2020
---Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act of 2019
---National Biodefense Strategy

Funding for Antimicrobial Resistance Programs
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.4100/S.1712: DISARM Act of 2019
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MED

16. Specific lobbying issues

Biodefense Research, Development and Procurement Issues (Non-funding)
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---H.R.6201: Families First Coronavirus Response Act of 2020
---Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act of 2019
---National Biodefense Strategy

Funding for Antimicrobial Resistance Programs
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.4100/S.1712: DISARM Act of 2019
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021

Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021

Funding for National Institutes of Health
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

21st Century Cures Act 2.0
---RFI from House Energy and Commerce Committee

Coronavirus (COVID-19) Pandemic
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---H.R.6201: Families First Coronavirus Response Act of 2020
---Home Administration of Part B Drugs
---Medicare Reimbursement Policies
---Patient Cost-Sharing and Smoothing
---Reasonable Pricing Provisions

Drug Pricing
---H.R.3: Lower Drug Costs Now Act of 2019
---H.R.19/S.3129: Lower Costs, More Cures Act of 2019
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.1188/S.366: Forcing Limits on Abusive and Tumultuous (FLAT) Prices Act of 2019
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---H.R.1503: Orange Book Transparency Act of 2019
---H.R.1520: Purple Book Continuity Act of 2019
---H.R.2376/S.1227: Prescription Pricing for the People Act of 2019
---H.R.2387: STOP GAMES Act of 2019
---H.R.3199 Terminating the Extension of Rights Misappropriated (TERM) Act of 2019
---H.R.3991 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---S.64: Preserve Access to Affordable Generics and Biosimilars Act of 2019
---S.1416/H.R.4398/H.R.3991/H.R.5133: Affordable Prescriptions for Patients Act of 2019
---S.1617: Second Look at Drug Patents Act of 2019
---S.1895: Lower Health Care Costs for Patients Act of 2019
---S.2543: Prescription Drug Pricing Reduction Act of 2019
---CMMI Authority
---General
---HHS Blueprint to lower drug prices and reduce out of pocket costs
---International Pricing Index Proposal
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2021
---Reasonable Pricing Provisions

Medicaid
---H.R.5741: Strengthening Innovation in Medicare and Medicaid Act of 2020
---Alternative payment arrangements for gene therapies
---Pricing and Rebates

Reimbursement and Coverage of Innovative Products
---H.R.3: Lower Drug Costs Now Act of 2019
---H.R.19/S.3129: Lower Costs, More Cures Act of 2019
---S.2326: New Opportunities for Value that Extend Lives (NOVEL) Act of 2019
---S.2543: Prescription Drug Pricing Reduction Act of 2019
---Administration Rebate Rule
---CMMI Authority
---HHS Blueprint to lower drug prices and reduce out of pocket costs
---Home Administration of Part B Drugs
---International Pricing Index Proposal
---Medicare Part B Physician-Administered Products
---Medicare Part D Prescription Drug Program
---Patient Cost-Sharing and Smoothing
---Step Therapy
---Support of Patient Premiums and Cost-Sharing Obligations
---Surprise Billing
---Value-based Contracting and Communications

Vaccines and Infectious Diseases
---H.R.5076/S.1872: Protecting Seniors through Immunizations Act of 2019

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Council of Economic Advisers (CEA), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Natl Economic Council (NEC), Office of the Vice President of the United States

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code SMB

16. Specific lobbying issues

Capital Market Enhancements
---Accredited Investor Definition
---Amended Definition of Smaller Reporting Company

Coronavirus (COVID-19) Small Business Loans (Non-Funding)
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Affiliation
---Eligibility

Funding for Coronavirus (COVID-19) Small Business Loans
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020

Proxy Advisory Services
---H.R.4015: Corporate Governance Reform and Transparency Act of 2017
---S.3614: Corporate Governance Fairness Act of 2018
---Impact of Policies on Small Public Companies

Sarbanes Oxley Section 404 (b)
---H.R.3886/S.452: Fostering Innovation Act of 2019
---Small Issuer Exemption

Short Selling Transparency

Small Business Innovation Research (SBIR) Program

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Securities & Exchange Commission (SEC), Small Business Administration (SBA), Treasury - Dept of

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

Biofuels (Non-Funding)
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---H.R.6379: Take Responsibility for Workers and Families Act of 2020
---Incentives for Sustainable Aviation Fuels
---Sustainable Aviation Fuels Tax Credit

Capital Formation Investment Incentives
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---H.R.6201: Families First Coronavirus Response Act of 2020
---Introduction of the American Innovation Act in the Senate
---Reform of Net Operating Loss Rules
---Reintroduction of the American Innovation Act in the House

Orphan Drug Issues
---Tax Credit

Qualified Small Business Stock (QSBS)

Renewable Chemicals/Bio-based Products (Non-Funding)
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---Investment Tax Credit
---Production Tax Credit

Research & Development Tax Credit Reforms
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---H.R.6201: Families First Coronavirus Response Act of 2020
---H.R.6379: Take Responsibility for Workers and Families Act of 2020
---Expensing of R&D Expenditures
---Incentives for Sustainable Aviation Fuels
---R&D Payroll Credit

Vaccine Injury Compensation Tax
---H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---H.R.1973/S.1654: Vaccine Access Improvement Act of 2019
---H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---H.R.6201: Families First Coronavirus Response Act of 2020

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Agriculture - Dept of (USDA), Treasury - Dept of

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

Committee on Foreign Investment in the United States (CFIUS)
---Implementation of Foreign Investment Risk Review Modernization Act (FIRRMA) of 2017

Drug Importation
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2021
---General

Drug Pricing
---International Pricing Index Proposal

Foreign Agricultural Biotechnology Laws and Regulations
---EU Ag-Biotech Policies and Regulations
---Korea Biotechnology Regulations

Intellectual Property International Enforcement
---China
---India

The United States-Mexico-Canada Agreement
---Ag-Biotech Provisions
---IP Provisions

US-China Trade Negotiations
---Ag Biotech Provisions
---IP Provisions

US-Japan Trade Agreement
---Ag-Biotech Provisions
---IP Provisions

US-Kenya Trade Agreement
---IP Provisions

US-UK Trade Agreement
---Ag-Biotech Provisions
---IP Provisions

World Trade Organization - Special 301 Submissions
---China
---India

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Treasury - Dept of, Agriculture - Dept of (USDA), Office of the Vice President of the United States, White House Office, Council of Economic Advisers (CEA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code SCI

16. Specific lobbying issues

Engineering Biology
---H.R.4373: Engineering Biology Research and Development Act
---Bioeconomy Research and Development Act Discussion Draft

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
No Yes